Eagle Pharmaceuticals, Inc. Finite-Lived Intangible Asset, Expected Amortization, after Year Five
Eagle Pharmaceuticals, Inc. had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $5.46 million as of 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2020-05-11
- 2020-03-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $5.46M.
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $5.79M.
- 2019-09-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $7.36M.
- 2019-06-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $7.36M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2020-03-31 | $5.46M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $5.79M 10-K · filed 2020-03-02 |
| 2019-09-30 | $7.36M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $7.36M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $7.56M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $7.36M 10-K · filed 2019-02-28 |
| 2018-09-30 | $8.93M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $8.93M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $10.34M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $9.86M 10-K · filed 2018-02-26 |
| 2017-09-30 | $12.02M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $17.83M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $17.83M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $17.83M 10-K · filed 2017-03-15 |
| 2016-09-30 | $18.89M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $8.16M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $8.16M 10-Q · filed 2016-05-10 |